Mirum Pharmaceuticals (MIRM) shares are in focus after Health Canada authorized LIVMARLI for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis, expanding the drug’s reach in a rare pediatric liver disease.

The Health Canada decision comes after a strong run in the share price, with Mirum’s 30 day share price return of 16.56% and 90 day share price return of 42.57% contributing to a very large 3 year total shareholder return. This suggests that momentum has been building around the story.

If this kind of regulatory-driven move interests you, it could be a good moment to broaden your watchlist with 27 healthcare AI stocks that our screener has surfaced as potential ideas in the wider healthcare space.

With Mirum shares up 16.56% over 30 days and 42.57% over 90 days, plus an indicated 13% to 14% discount to both analyst targets and an intrinsic estimate, investors now have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 5.3% Undervalued

Mirum Pharmaceuticals last closed at $100.91, compared with a widely followed narrative fair value of $106.60, which is based on detailed forecasts and a specific discount rate of 7.17%.

Multiple late-stage pipeline catalysts, including three pivotal study readouts (VISTAS, VANTAGE, EXPAND) over the next 24 months and the initiation of the Phase II Fragile X study, set the stage for further product label expansions and new indication launches, underpinning future revenue diversification and potential earnings acceleration.

Curious how a rare disease franchise, a rich late stage pipeline and rising margin assumptions all feed into that fair value? The narrative leans on ambitious revenue compounding, a meaningful swing into profitability and a premium future earnings multiple that is usually reserved for much larger names. Want to see exactly which forecasts have to land for $106.60 to make sense?

Result: Fair Value of $106.60 (UNDERVALUED)

However, the story could change quickly if Livmarli underperforms against expectations or if late stage trials like VISTAS or EXPAND deliver weaker than hoped data.

Build Your Own Mirum Pharmaceuticals Narrative

If you look at this and think the assumptions feel off, or you prefer to stress test the numbers yourself, you can build a custom view of Mirum in a few minutes with Do it your way

A great starting point for your Mirum Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop with one company, use the Simply Wall Street Screener to surface fresh ideas now.

• Target quality at a discount by scanning our 51 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect them.
• Strengthen your income stream by reviewing 14 dividend fortresses that offer higher yields while still focusing on durability.
• Prioritize resilience by checking 83 resilient stocks with low risk scores that our model flags with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.